Myriad Genetics (MYGN) Wells Fargo 21st Annual Healthcare Conference summary

Key financial and operational drivers

• Q2 revenues declined 11% and ASPs fell 9%, prompting reduced guidance due to ongoing softness in prenatal testing and reimbursement pressure in hereditary cancer testing.

• Strategic portfolio review underway, with actions expected in coming months to strengthen financial position and focus on cancer care.

• Project Ascend launched to modernize operations, improve productivity, and drive both cost savings and revenue synergies, with initial benefits expected in 2027 and further actions into 2028.

• Guidance set conservatively, assuming no improvement in ASPs, no material impact from new products or additional salespeople, and historical seasonality patterns.

• Liquidity remains strong at $190 million, with investments prioritized for growth in cancer care.

Revenue cycle management and reimbursement

• Revenue cycle management optimization and strategic payer alignment initiatives are underway to address reimbursement friction, especially in hereditary cancer testing.

• Efforts focus on improving billing, collections, and aligning technology with medical policy and guidelines for long-term payer relationships.

• Current reimbursement pressures are not due to changes in medical policy but rather payer-specific actions; future efforts aim to expand coverage and access.

Product and market performance

• MyRisk hereditary cancer test continues strong volume growth, driven by new product features, dedicated sales teams, and recent guideline changes expanding testing recommendations.

• MRD (minimal residual disease) test expanded to new cancer types, with early access sites showing positive feedback and operational efficiency; reimbursement for breast cancer expected in H1 2027.

• GeneSight mental health test maintains market leadership and steady volume growth, with ASP improvements driven by payer engagement and biomarker legislation.

• Prolaris + AI launched, offering molecular and AI insights for prostate cancer surveillance, generating early interest and expected to improve competitive positioning.

• FirstGene prenatal test launched, differentiated by early gestational testing and comprehensive results; early feedback positive but not yet material to guidance.